2022 Department of Medicine Grand Rounds | Antifungal Resistance and Its Implications in the Management of Mold Infections
In the last few decades there has been an issue of increased antifunagl use - both in the increasingly vulnerable immunocompromised patients and in the environment, for agriculture purposes: de novo resistance in the fungi (especially molds) at the time of infection and secondarily in the patient upon exposure to antifunagl drugs. To address this topic, it is imperative to provide the most current updates in mycology in order to bridge any gaps in knowledge.
This activity is necessary for City of Hope clinicians, as they manage highly immunocompromised patients with cancer, especially those with hematologic malignancies and stem cell transplantation. They manage an increasingly complex patient population, with many patients having refractory disease requiring prolonged courses of antifungal putting them at high risk for resistant fungal infections. An expert at the forefront of bench research in mycology will provide information on the basic biology of resistance and intereventions.
Physician faculty and APP in hematology/hematopoietic cell transplantation who actively provide treatment to such patients.
- Identify risk factors for antifungal resistance in molds.
- Appreciate the mechanism of resistance.
- Evaluate for antifungal resistance and interpret data.
- Assess antifungal management.
- Discuss possible barriers and biases which may impact patient care (i.e., race, ethnicity, language, gender identity/orientation, age, socioeconomic status, attitudes, feelings, or other characteristics).
Virtual Meeting- Zoom
Thomas J. Walsh, MD, PhD (Hon), FIDSA, FAAM, FECMM Founding Director, Center for Innovative Therapeutics and Diagnostics; Henry Schueler Foundation Scholar; Investigator of Emerging Infectious Diseases of the Save Our Sick Kids Foundation; Ajunct Professor of Pathology, The Johns Hopkins University School of Medicine; Ajunct Professor of Medicine, Microbiology, and Immunology, University of Maryland School of Medicine
Dr. Walsh disclosed that he receives Grant/Research Support form Amplyx, Astellas, Merck, Scynexis, T2 Biosystems, Tetraphase; and is a Consultant for Amplyx, Astellas, ContraFect, Gilead, Merck, Methylgene, Partner Therapeutics, Pfizer, Scynexis and T2 Biosystems.
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this live webinar for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1 Credit™ 1.0
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
- 1.00 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this 2022 Department of Medicine Grand Rounds | Antifungal Resistance and Its Implications in the Management of Mold Infections for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Attendance